Tuesday 23 January 2018 ShareProphets: The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Snap up that Biotech! (Part 1/3) – Buy Optibiotix to double

By James Parter | Sunday 2 November 2014

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Today I start a collection of three biotech companies that I think have brilliant upside potential. Biotech firms can fly on bullish news on their products and these are three firms that I am banking on to do that. These could be genuine multibaggers if they meet expectations or grind lower if they do not.

Number one company that I will look at is Optibiotix Health (OPTI), a microbiome company that the Sheriff of AIM looked at when it reversed into total flop shell Ducat Ventures. Ducat was a tin shop company but shareholders have been given life after death and this £7 million pound company could be worth double that I think.

That would put the shares (now 10.125p) at 20p and the market capitalisation would only be about £15 million and Optibiotix already has a wad of cash. CEO Stephen O'Hara is an astute fellow and the company has already screened bacteria that can reduce cholesterol by up to 82%! I could do with that

It's a ginormous market it is tapping with the human microbiome and 4D Pharma is in the same area. 4D is worth £172 million and does not have an awful lot more than Optibiotix. OK it’s a bit further down the proverbial path but Stephen O'Hara has already laid the foundations with the big pharma companies as he talked about at the recent Shareprophets seminar – the video of which is HERE. The price gap is astounding.

Optibiotix only listed in August. It is under the radar and set to fly. The science behind the human microbiome, particularly how changes to the way microbes work in our bodies can impact our health, presents a huge opportunity for us to address many widely experienced diseases and a chance to significantly improve lives worldwide. We are at the frontline of research into using microbiome science to tackle weight related health problems and this move to AIM provides us with the support we need to advance our pipeline of products that support and sustain weight loss and reduce lipid and cholesterol levels.

O'Hara has not hung aroundstarting studies to get products into foods with Nizo Food Research, getting together a top quality scientific advisory group and telling investors that the product worked in yoghurts without negative effects.

Optibiotix is set for a barnstorming few months and it is my first of three biotech picks to fly. Look for 20p or nearly 100% upside over six months. Do not be disappointed if it does not move immediately but wait for O'Hara to deliver the real news that will create value. A tie up with a big firm would do wonders for the share price. 

p.s. Next time I will look at biotech firm dealing with urological disorders. Keep your eyes on this one. The third one is magical...

Filed under:

Never miss a story.

This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on OPTI



  1. Congratulations – top tip. Thanks for drawing my attention to this one. Nice to see a tip for a non-oiler or IT set-up – or MINEX yawn yawn yawn. I can’t wait for Part 2 – keep up the good work. You might want to look at C4XD just IPOd – novel NMR work on drug target analysis. Not sure how they will make money excpet as contract services. But the technology is very interesting

Enter your comment below. Fields marked * are required. You must preview your comment first before finally posting.

Site by Everywhen